Trial Profile
A First in Human, Randomized, Double-blind, Placebo-controlled, Single Ascending Dose Trial Assessing Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of a Single Subcutaneous Dose of ZP7570 in Healthy Subjects
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 04 Nov 2021
Price :
$35
*
At a glance
- Drugs Dapiglutide (Primary)
- Indications Gastrointestinal disorders; Short bowel syndrome
- Focus Adverse reactions; First in man
- Sponsors Zealand Pharma
- 12 Nov 2020 According to a Zealand Pharma media release, the company plans to publish data from this trial at a scientific conference in 2021.
- 12 Nov 2020 Results published in the Zealand Pharma financial media release.
- 12 Nov 2020 Status changed from recruiting to completed, according to a Zealand Pharma media release.